This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Key Event Title
|Level of Biological Organization|
Key Event Components
Key Event Overview
AOPs Including This Key Event
|AOP Name||Role of event in AOP||Point of Contact||Author Status||OECD Status|
|Inhibition fatty acid beta oxidation leading to nonalcoholic steatohepatisis (NASH)||AdverseOutcome||Lyle Burgoon (send email)||Open for adoption|
|endocrine disrupting effect||AdverseOutcome||Fei Li (send email)||Under development: Not open for comment. Do not cite|
|All life stages||High|
Key Event Description
Biological state: steatohepatisis is steatosis (fatty liver) presenting with inflammation.
Biological compartment: liver.
Role in biology: Steatohepatisis is a disease and adverse endpoint. If this state continues, it will eventually lead to fibrosis and cirrhosis of the liver.
How It Is Measured or Detected
Steatohepatitis is typically measured histologically. Fatty liver is noticed by oil red O staining, although it also may be noted using lipidomics. Inflammatory cell infiltration is typically noted histologically.
Domain of Applicability
NASH (non-alcoholic steatohepatitis) can occur in any organism that contains a liver.
Regulatory Significance of the Adverse Outcome
The precursor state to NASH (non-alcoholic steatohepatitis), steatosis, has been used in US EPA IRIS assessments as an adverse outcome.